Compare GLDD & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | DRTS |
|---|---|---|
| Founded | 1890 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 978.2M |
| IPO Year | 2007 | N/A |
| Metric | GLDD | DRTS |
|---|---|---|
| Price | $17.00 | $9.35 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $17.00 | $8.67 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $7.56 | $699.98 |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.37 | $2.87 |
| 52 Week High | $17.02 | $11.62 |
| Indicator | GLDD | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 48.44 |
| Support Level | $14.60 | $6.59 |
| Resistance Level | N/A | $11.62 |
| Average True Range (ATR) | 0.03 | 1.06 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 80.00 | 16.30 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.